Detail akcie Ultragenyx Pharm online

Business Summary: Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Ultragenyx Pharmaceutical Inc revenues increased 20% to $434.2M. Net loss decreased 14% to $606.6M. Revenues reflect Crysvita non-cash collaboration royalty revenue segment increase from $21.7M to $182.7M, Crysvita segment increase of 77% to $75.7M, Latin America segment increase of 73% to $77.3M, North America segment increase of 9% to $307.1M.